Cancer cells undergo accelerated evolutionary changes; thus, under the pressure of novel generations of EGFR TKIs, we should expect to see new mechanisms of resistance.
Arkadiusz Z. Dudek, MD, PhD
Advertisement
Articles by Arkadiusz Z. Dudek, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Ziftomenib Plus 7+3 Yields High Response Rates in Newly Diagnosed AML
2
Arlo-Cel Produces Deep Responses in Pretreated R/R Multiple Myeloma
3
Pirtobrutinib Plus Venetoclax/Rituximab Improves PFS in Pretreated CLL
4
Liso-Cel Demonstrates Real-World Efficacy in Relapsed/Refractory MCL
5